Alinia is a drug owned by Romark Laboratories. It is protected by 5 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 03, 2017. Details of Alinia's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5965590 | Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide |
Jul, 2017
(8 years ago) |
Expired
|
| US5968961 | Pharmaceutical compositions of tizoxanide and nitazoxanide |
May, 2017
(8 years ago) |
Expired
|
| US6117894 | Acid stabilized pharmaceutical compositions of tizoxanide and nitazoxanide |
May, 2017
(8 years ago) |
Expired
|
| US6020353 | 2-(hydroxy)-N-(5-nitro-2-thiazolyl) benzamide |
Sep, 2014
(11 years ago) |
Expired
|
| US5578621 | Benzamide derivatives |
Nov, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but
Alinia is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Alinia's family patents as well as insights into
ongoing legal events
on those patents.
Alinia's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Alinia's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 03, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Alinia Generic API suppliers:
Nitazoxanide is the generic name for the brand Alinia. 3 different companies have already filed for the generic of Alinia, with Ani Pharms having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Alinia's generic
About Alinia
Alinia is a drug owned by Romark Laboratories. It is used for treating parasitic infections, including Cryptosporidium parvum, in immunocompromised mammals. Alinia uses Nitazoxanide as an active ingredient. Alinia was launched by Romark in 2002.
Approval Date:
Alinia was approved by FDA for market use on 22 November, 2002.
Active Ingredient:
Alinia uses Nitazoxanide as the active ingredient. Check out other Drugs and Companies using Nitazoxanide ingredient
Treatment:
Alinia is used for treating parasitic infections, including Cryptosporidium parvum, in immunocompromised mammals.
Dosage:
Alinia is available in the following dosage forms - tablet form for oral use, for suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG/5ML | FOR SUSPENSION | Discontinued | ORAL |
| 500MG | TABLET | Discontinued | ORAL |